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Purpose: A review of treat-and-extend regimens (TERs) with intravitreal anti–vascular
endothelial growth factor agents in retinal diseases.
Methods: There is a lack of consensus on the deﬁnition and optimal application of TER
in clinical practice. This article describes the supporting evidence and subsequent
development of a generic algorithm for TER dosing with anti–vascular endothelial growth
factor agents, considering factors such as criteria for extension.
Results: A TER algorithm was developed; TER is deﬁned as an individualized proactive
dosing regimen usually initiated by monthly injections until a maximal clinical response is
observed (frequently determined by optical coherence tomography), followed by increasing
intervals between injections (and evaluations) depending on disease activity. The TER
regimen has emerged as an effective approach to tailoring the dosing regimen and for
reducing treatment burden (visits and injections) compared with ﬁxed monthly dosing or
monthly visits with optical coherence tomography–guided regimens (as-needed or pro re
nata). It is also considered a suitable approach in many retinal diseases managed with
intravitreal anti–vascular endothelial growth factor therapy, given that all eyes differ in the
need for repeat injections.
Conclusion: It is hoped that this practical review and TER algorithm will be of beneﬁt to
health care professionals interested in the management of retinal diseases.
RETINA 35:1489–1506, 2015
Three retinal diseases (neovascular age-related mac-ular degeneration [nAMD], diabetic macular edema
[DME], and retinal vein occlusion [RVO]) are associ-
ated with a major health care burden in Western coun-
tries, mainly because of their chronic nature and poor
visual outcomes if left untreated. Although the under-
lying etiology of these diseases is complex, there is now
evidence to show that vascular endothelial growth factor
(VEGF) plays a key role in their pathogenesis.1–3 This
provides a common rationale for targeting VEGF in
retinal diseases. Anti-VEGF agents are effective
options, but monthly injections and monthly clinic vis-
its may reduce long-term compliance and increase
costs. Monthly approaches have their origins in the
standard design of pivotal randomized studies.
To optimize the beneﬁt:risk ratio and cost-
effectiveness of anti-VEGF agents, a number of ﬂexible
dosing strategies are increasingly being used in clinical
practice. These include a variety of as-needed (pro re
nata [PRN]) approaches (i.e., regular follow-up with
treatment that is determined mostly by recurrent macular
ﬂuid on optical coherence tomography [OCT])4–6 and
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treat-and-extend regimens (TERs), which may involve
ﬁxed treatment intervals until clinical remission, usually
determined by OCT, followed by increasing treat-
ment intervals. A retrospective, observational study
of intravitreal ranibizumab in nAMD that examined
differences between management in 2007 and 2010
(in 125 eyes) showed that the visual gain was greater
(+6.0 vs. +0.7 Early Treatment Diabetic Retinopathy
Study letters; P = 0.0003) and eyes also received more
injections (5.0 vs. 3.8; P , 0.0001) in 2010 than in
2007. The temporal change may be because of a number
of factors, including the use of alternative strategies, such
as TER.7 However, this study did not directly assess the
impact of TER or alternative strategies, and large-scale
comparisons in different populations are lacking. There
is also wide variation in dosing regimen selection
(including TER) in clinical practice8 and across disease
areas.9 Evaluating the evidence and developing a consen-
sus on the most effective TER protocol would potentially
improve regimen selection in clinical practice and enable
physicians to understand the rationale for TER, resulting
in more considered dosing choices. TER was also re-
garded as a ﬂexible dosing strategy to reduce retreatment
burden in the recently updated EURETINA guidelines.10
There is also evidence to suggest that intraindividual
retreatment intervals are stable but interindividual recur-
rence intervals are variable.11,12 This is an ideal basis for
individualized treatment plans with TER.
Objectives and Methods
The aim of this report is to provide a review and
consensus on the best practice approach to the use of
TER with anti-VEGF agents (intravitreal ranibizumab,
intravitreal bevacizumab, or intravitreal aﬂibercept) in
retinal diseases based on currently available evidence.
The review was developed following a roundtable
discussion by international retina specialists (consensus
panel), which was held in Rome, Italy (26 January
2014), and was also reviewed at a second roundtable
meeting held in Tokyo, Japan (01 April, 2014). During
the initial meeting, scientiﬁc evidence and clinical cases
were discussed, followed by the development of an
algorithm on the recommended approach to TER; it is
envisaged that this algorithm will be useful to oph-
thalmologists and health care providers with an interest
in the long-term management of patients with retinal
disease. The scientiﬁc evidence has been graded using
European guidance (see Appendix 1, Supplemental
Digital Content 1, http://links.lww.com/IAE/A346).13
Scientiﬁc Evidence
TER studies. There are 11 published TER studies in
more than 1,000 patients with nAMD (Table 1)14–24
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Table 1. An Overview of “TER” Studies With Anti-VEGF Agents in nAMD
Reference Design Treatment Efﬁcacy Results Safety Results Level
Engelbert et al14 • Retrospective 3 monthly injections (IVB or IVR)
followed by intervals increasing by
2 weeks per visit to a maximum of
10 weeks
• Mean VA: improved from
20/80 (BL) to 20/40 (Month
1); maintained at Year 3
(P , 0.04)
No injection-related
complications, such as
endophthalmitis or retinal
detachment
4
• FU: 36 months • Mean OCT CRT:
decreased from 320 mm
(BL) to 230 mm (Month 1);
maintained at 180 mm
from Month 3 to Year 3
(P , 0.02)
• Type 3 NV/RAP • Mean injections (n): 7
(Year 1), 6 (Year 2), 7
(Year 3)
• 10 patients (11 eyes)
Engelbert et al15 • Retrospective 3 monthly injections (IVB or IVR)
followed by intervals increasing by
2 weeks per visit to a maximum of
10 weeks
• Median logMAR VA:
remained stable from 0.53
(BL) to 0.52 at Year 3
(P = 0.68)
15 eyes continued to have SRF;
1 eye developed geographic
atrophy; 0 eyes developed
submacular hemorrhage (over
a 540-month period)
4
• FU: 36 months
• Type 1 (subretinal
pigment epithelium) NV
• Mean injections (n): 12
(Year 2), 20 (Year 3)
• 16 patients (18 eyes)
Gupta et al16 • Retrospective Monthly injections (IVR) until no ﬂuid on
OCT followed by intervals increasing
by 2 weeks until exudation recurred
• Mean VA: improved from
20/135 (BL) to 20/83 at
Year 2 (P = 0.002)
No adverse ocular or systemic
events were reported during FU
4
• FU: 24 months • Mean OCT CRT:
decreased from 303 mm
(BL) to 238 mm at Year 1
(P , 0.001)
• Treatment-naive
nAMD
• Mean injections (n): 8.36
(Year 1), 7.45 (Year 2)
• 92 patients (92 eyes) • Mean extension period:
79.9 days
Shienbaum et al17 • Retrospective Monthly injections (IVB) until no ﬂuid on
OCT followed by intervals increasing
by 2 weeks until exudation recurred
• Mean VA: improved from
20/230 (BL) to 20/106 at
Year 2 (P , 0.001)
No adverse ocular or systemic
events were reported
throughout the study
4
• FU: 24 months • Mean OCT CRT:
decreased from 316 mm
to 239 mm at Year 1 (P ,
0.001)
• Treatment-naive
nAMD
• Mean injections (n): 7.94
(Year 1)
• 73 patients (74 eyes)
(continued on next page)
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Table 1. (Continued )
Reference Design Treatment Efﬁcacy Results Safety Results Level
Fung et al18 • Randomized Monthly IVR (0.5 mg or 2.0 mg)
followed by TER (up to 8-week
intervals) unless exudation recurred
• Main gain in VA (ETDRS
letters): 4.1 (2.0 mg) and
3.0 (0.5 mg) at Month 12
No adverse events in either group 2
• FU: 12 months • Mean decline in CFT:
−40 mm (2.0 mg) and
−108 mm (0.5 mg) at
Month 6
• Recalcitrant nAMD • Area of leakage (FA):
−0.92 mm2 (2.0 mg) and
−1.30 mm2 (0.5 mg) at
Month 6
• 9 patients (9 eyes) • Mean injections (n): 6
(2.0 mg) and 5 (0.5 mg)
Toalster et al19 • Prospective,
nonrandomized
Monthly IVR until no ﬂuid on OCT
followed by intervals increasing by
2 weeks until exudation recurred
• Mean VA: improved from
20/62 (BL) to 20/46
(Month 12)
No adverse events reported 3
• FU: 12 months • Mean OCT CRT:
improved from 330.9 mm
(BL) to 266.3 mm (Month
12)
• Treatment-naive
nAMD
• Mean injections (n): 8
• 45 patients
Abedi et al20 • Prospective cohort Monthly IVB or IVR until no CNV
activity (no ﬂuid on OCT, loss of .5
letters, or persistent/recurrent
hemorrhage) followed by increasing
intervals of 2 weeks (maximum 12)
• Mean change in ETDRS
letters was +9.5 (Month
12) and +8.0 (Month 24)
Not available 3
• FU: 24 months • Mean injections/clinic
visits (n): 8.6 (Year 1) and
5.6 (Year 2)
• nAMD (CNV)
• 120 patients
Rush et al21 • Retrospective 3 monthly injections (IVB) until no ﬂuid
on OCT followed by intervals
increasing by 2 weeks up to 12
weeks; if recurrence, interval
reduced by 2 weeks
• Mean VA: improved from
20/55 (BL) to 20/44
(Month 12) (P , 0.001)
Not available 4
• FU: 12 months • Mean OCT CMT:
improved from 373.1 mm
(BL) to 305.5 mm (Month
12)
• nAMD • Mean injections (n): 9.2
• 230 eyes
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Table 1. (Continued )
Reference Design Treatment Efﬁcacy Results Safety Results Level
Rush et al22 • Retrospective 3 monthly injections (IVB) until no ﬂuid
on OCT followed by intervals
increasing by 2 weeks up to
a maximum intervisit interval; if ﬂuid
recurrence, BCVA dropped by 2
lines, or leakage on FA, interval
reduced by 2 weeks
• Mean change in CNV
size: 1.9 mm2 (BL); 1.66
mm2 (Month 2); 1.60 mm2
(Month 6); 1.50 mm2
(Month 12)
Not available 4
• FU: 12 months • Mean logMAR VA:
changed from 0.47 (BL) to
0.33 (Month 12)
• nAMD (CNV) • Mean injections (n): 9.3
• 123 patients
Berg et al23 (LUCAS) • Randomized,
double-blind
IVB or IVR monthly until no ﬂuid on
OCT followed by intervals increasing
by 2 weeks up to 12 weeks; if
recurrence, interval reduced by
2 weeks until macula dry
• Mean ETDRS letters:
69.6 (IVR) and 67.2 (IVB)
at Month 12
APTC-ATEs: 4.5% (IVR) versus
1.4% (IVB) (P , 0.05)
2
• FU: 12 months • Mean change in CRT:
−120 mm (IVR) and −112
mm (IVB) at Month 12
Nonfatal MI: 2.7% (IVR) versus
0% (IVB) (P = 0.014)
• Treatment-naive
nAMD
• Mean injections (n): 8.0
(IVR) and 8.9 (IVB) (P =
0.001)
Nonfatal stroke: 1.4% (IVR) versus
0.9% (IVB)
• 441 patients Injury or procedural
complications: 3.2% (IVR)
versus 0.5% (IVB) (P = 0.033)
One vascular death in each group
Rayess et al24 • Retrospective Monthly IVB or IVR until no CNV
activity on slit-lamp biomicroscopy/
OCT followed by intervals increasing
by 2 weeks; if signs of exudate,
interval reduced by 2 weeks
• Mean change in ETDRS
letters: +11.6 (Year 1),
+10.7 (Year 2), and +13.6
(Year 3)
Not available 4
• FU: 36 months • Mean change in CRT:
351 mm (BL), 285 mm
(Year 1), 275 mm (Year 2),
and 276 mm (Year 3) (all
P , 0.001)
• Treatment-naive
nAMD
• Mean injections (n): 7.6
(Year 1), 5.7 (Year 2), and
5.8 (Year 3)
• 196 patients (212 eyes)
APTC-ATE, Antiplatelet Trialists’ Collaboration–deﬁned arterial thromboembolic event; BCVA, best-corrected visual acuity; BL, baseline; CFT, central foveal thickness; CMT, central
macular thickness; CNV, choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; FU, follow-up; IVB, intravitreal bevacizumab;
IVR, intravitreal ranibizumab; LogMAR, logarithm of the minimum angle of resolution; MI, myocardial infarction; nAMD, neovascular age-related macular degeneration; NV, neo-
vascularization; RAP, retinal angiomatous proliferation; SRF, subretinal ﬂuid; TER, treat-and-extend; VA, visual acuity.
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and 3 comparator studies against PRN approaches
(Table 2).25–27 The studies showed an improvement
in both visual and anatomical outcomes (central foveal
thickness/central retinal thickness/choroidal NV size)
using TER, and this approach was associated with
greater (and possibly earlier) visual improvements
compared with PRN over a period ranging from 6
months to 36 months, with mean injections around 8
in the ﬁrst year and around 6 to 7 in the second year.
There were no major safety concerns with the TER
approach, and no eyes developed submacular hemor-
rhage during an extended follow-up period. The TER
approach was similar across studies, with most using
a 3-monthly loading scheme until no ﬂuid was seen on
OCT followed by 2-week extension intervals up to
a maximum of 10 weeks to 12 weeks unless ﬂuid or
hemorrhage recurred.
The criteria for treatment extension in each study are
summarized in Table 3.14–21,23,24 In the majority of
studies, a dry macula was required before extension
(i.e., no ﬂuid on OCT and no persistent or new hemor-
rhage). Resolution of pigment epithelial detachment
was not required before extension; this was particularly
relevant in eyes with Type 1 (subretinal pigment epi-
thelium) neovascularization (NV) that will often con-
tinue to manifest pigment epithelial detachment after
a loading scheme. A number of studies also required
a stable disease state before extension and used no
change or increase in vision loss or central retinal thick-
ness as markers for treatment change. Fluid recurrence
was usually used as a marker for interval shortening. It
is expected that ﬂuid recurrence will occur at some
stage during an extension phase (making it an important
marker); it can, therefore, be used to reﬁne the optimal
dosing interval during the follow-up period. At present,
there is no optimal approach or guidance for switching
from PRN to TER. Changing dosing regimen may be
guided by the criteria for extension that have already
been described.
There are few studies using TER in macular edema
(ME) secondary to RVO or DME (Table 4).28–30 The
consensus panel found the evidence for TER in
ME/RVO and DME too scarce to provide general guid-
ance at present. However, based on clinical experience,
the proposed TER algorithm will be applicable to
ME/RVO and DME. The TER attempts to individualize
the dosing regimen and reduce treatment burden (both
visits and injections) compared with ﬁxed monthly dos-
ing or monthly visits with OCT-guided regimens, and it
can lead to fewer visits (albeit more injections, particu-
larly in the ﬁrst year of therapy) compared with PRN
dosing. These are also considerations for ME/RVO and
DME patients. It is also hoped that some of the ongoing
TER studies (Table 5) will add further clarity. This will
also be valuable in improving the evidence-based treat-
ment guidelines as most of the studies (Tables 1, 2, and
4) are low grade (Level 3–4 evidence) and not registra-
tion studies.
Extended follow-up (non-TER) studies. The majority
of studies using a TER approach to treatment were
performed using intravitreal ranibizumab or bevacizu-
mab. The evidence for intravitreal aﬂibercept is largely
supported by studies that used a 3- to 5-monthly 2 mg
dosing scheme followed by dosing every 8 weeks
(2q8). Although these were not TER schedules, they
are useful in that they illustrate outcomes using an
extended dosing regimen in a randomized setting and
are registration studies (Level 1 evidence).
In 2 multicenter, active-controlled, randomized stud-
ies (VIEW 1 and VIEW 2), 2,419 patients with nAMD
and subfoveal choroidal neovascularization were ran-
domized to intravitreal aﬂibercept 0.5 mg or 2.0 mg
monthly or 2 mg every 2 months after 3 monthly
loading doses (2q8) or intravitreal ranibizumab 0.5 mg
monthly.31 All intravitreal aﬂibercept groups were non-
inferior to monthly intravitreal ranibizumab for vision
maintenance at Week 52 (i.e., loss of ,15 Early Treat-
ment Diabetic Retinopathy Study letters). Intravitreal
aﬂibercept (any regimen) and monthly intravitreal rani-
bizumab were equally effective in improving best-
corrected visual acuity over a 96-week follow-up, but
the intravitreal aﬂibercept 2q8 group was associated
with an average of 5 fewer injections.32 In addition to
it being given at a higher dose, it is possible that the
longer dosing regimen with intravitreal aﬂibercept 2.0
mg compared with intravitreal ranibizumab 0.5 mg
observed in the VIEW studies may be linked to differ-
ences in binding afﬁnity and a longer intravitreal
half-life (approximately 9.0 days vs. 7.1 days, respec-
tively).33 In the 18-month follow-up of the GALILEO
study, visual and anatomical improvements observed
with monthly intravitreal aﬂibercept dosing in patients
with ME secondary to central RVO were maintained
when the treatment intervals were extended.34 Intravi-
treal aﬂibercept 2q8 has also been shown to be effective
in DME patients in two similarly designed, active-
controlled, randomized studies (VIVID-DME and
VISTA-DME).35
Only one large noninferiority study in DME patients
(RETAIN) used a treatment approach with extended
and reduced follow-up intervals and was considered an
“extend-and-treat” study.36 In RETAIN, patients with
DME were randomized to intravitreal ranibizumab with
the possibility to modify intervals with laser (Group 1;
n = 121) or without laser (Group 2; n = 128) and intra-
vitreal ranibizumab PRN (Group 3; n = 123) over
a 24-month follow-up. Both approaches with modiﬁed
intervals were noninferior to PRN based on mean
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Table 2. An Overview of Studies Comparing TER and PRN Dosing Strategies With Anti-VEGF Agents in nAMD
Reference Design Treatment Outcomes Conclusions Level
Oubraham et al25 • Retrospective,
comparator
• IVR • Mean gain in VA: +10.8 (TER group)
and +2.3 (PRN group) at 1 year (P =
0.036)
TER associated with signiﬁcantly
greater VA improvements than
PRN; mean injections were higher
but visits were comparable
3
• FU: 12 months • PRN group (n = 52) and
TER group (n = 38)
• Mean injections (n): 7.8 (TER group)
and 5.2 (PRN group) (P , 0.001)
• nAMD • FU visits (n): 8.5 (TER group) and 8.8
(PRN group)
• 90 patients
Hatz and
Pruente26
• Retrospective,
comparator, switch
• IVR • Mean VA improved from: 20/42 (BL)
to 20/36 at 6 months (switch group)
Switching to TER associated with
improvement in VA but with more
injections
3
• FU: 6 months • Switch from PRN to
TER group (n = 142)
• Mean injections per month (n) was:
0.47 (PRN) and 0.76 (TER)
• nAMD • Treatment-naive TER
group (n = 43)
• Visits per month: 1.10 (PRN) and
0.76 (TER) (P = 0.008)
TER was associated with
signiﬁcantly fewer patient visits
• 185 eyes
Calvo et al27 • Retrospective,
comparator
• IVR • Kaplan–Meier survival rates (loss
,0.3 units logMAR) were 90.9% (TER)
and 89.7% (treat and observe)
TER and treat-and-observe regimens
showed similar visual outcomes
after a 3-year period
3
• FU: 36 months • VA improved: 42.4% (TER) and
24.1% (treat and observe)
• nAMD (CNV) • TER group (n = 30) and
treat-and-observe group
(n = 30)
• No ﬁnal VA differences (P . 0.05)
• 60 patients • Injections (n): 20.31 (TER) and 18.41
(treat and observe)
BL, baseline; CNV, choroidal neovascularization; FU, follow-up; IVR, intravitreal ranibizumab; LogMAR, logarithm of the minimum angle of resolution; nAMD, neovascular age-related
macular degeneration; PRN, pro re nata; TER, treat-and-extend; VA, visual acuity.
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average best-corrected visual acuity change from base-
line to Month 1 through Month 12 (+5.9 and +6.1 vs.
+6.2 letters; both P , 0.0001). There was an approxi-
mately 40% reduction in patient visits in the groups
with modiﬁed intervals. The design of RETAIN high-
lights that proactive approaches, such as TER, may be
more important to consider in nAMD because it is
a more aggressive condition than DME.
Monitoring TER Outcomes Following
Anti-VEGF TER
Imaging modalities. It is important to use the most
accurate methods to monitor long-term follow-up. The
TER studies outlined in Table 3 mainly used spectral-
domain OCT or time-domain OCT for measuring ﬂuid
as the primary method for treatment extension, and
some studies used ﬂuorescein angiography (FA) as
a secondary method, particularly if interval shortening
was being considered. Leakage on FA, even if not
shown on OCT, was one criterion for reverting back
to more intensive treatment. We assume that all OCT
techniques were performed in accordance with estab-
lished protocols; however, none of the studies corre-
lated the ﬁndings if several OCT techniques were
used, and they were not Level 1 type studies.
The reliance on OCT to guide dosing intervals may
also be confounded by the data showing that there is
often low agreement between spectral-domain OCT and
time-domain OCT, particularly for advanced features,
such as hard exudates,37 and also for retinal thickness
measurements.38 A number of studies have reported that
spectral-domain OCT may be superior to time-domain
OCT for detecting subretinal ﬂuid (SRF)39,40 and for
identifying abnormalities in the absence of ﬂuorescein
leakage from choroidal neovascularization.41 Taken
together, these ﬁndings indicate that an absence of ﬂuid
on spectral-domain OCT or time-domain OCT, resolu-
tion of persistent hemorrhage and no new-onset hemor-
rhage, and no leakage on FA are a benchmark for
establishing accurate treatment intervals for TER in
nAMD. Fluorescein angiography is also a sensitive tech-
nique in detecting leakage associated with ME, making
spectral-domain OCT and FA useful for obtaining
a comprehensive evaluation in other retinal diseases.42
The vitreomacular interface, as imaged with OCT,
may also have an inﬂuence on treatment intervals in
nAMD patients using TER.43 In one study of 64 nAMD
patients, the mean visual acuity in the non-vitreomacular
adhesion group (n = 49) was 20/66 compared with 20/67
in the vitreomacular adhesion group (n = 15) at Year 1.
The mean central retinal thickness values were 264 mm
and 308 mm, respectively. The mean total number of
injections was 7.6 (non-vitreomacular adhesion) and
8.7 (vitreomacular adhesion) (P = 0.028), and the mean
interval between injections was 7.5 weeks versus
6.3 weeks (P = 0.022). Applying more sensitive imaging
techniques could result in a more accurate prediction of
treatment intervals. Other imaging modalities may be
considered as optional; however, they are not required
for using a TER approach in most patients.
Baseline characteristics. Several studies have exam-
ined the relationship between baseline characteristics
and long-term outcomes in an attempt to determine
predictors of clinical outcomes and to identify eyes
that would beneﬁt most from a TER strategy; this is
particularly relevant in today’s environment because
treatment is often started earlier in patients with better
baseline visual acuity. One retrospective review
involving 230 eyes with nAMD that were treated with
intravitreal bevacizumab using TER found that thinner
central macular thickness was independently associ-
ated with fewer injections.21
A more detailed analysis of 185 nAMD patients
(210 eyes) treated with anti-VEGF TER therapy over
a mean follow-up of 3.5 years (range, 1–6.6 years)
showed that the mean visual acuity improved from
baseline to ﬁnal visit in eyes with all neovascular
lesion subtypes except Type 3 (intraretina) NV (Type
1 [subretinal pigment epithelium] NV [20/69–20/55];
Type 2 [subretinal pigment epithelium] NV [20/139–
20/92]; Type 3 [retinal angiomatous proliferation] NV
[20/78–20/83]; and mixed lesions [20/171–20/150]).44
Most patients received intravitreal ranibizumab only
(59%). The rest received a combination of intravitreal
ranibizumab and aﬂibercept (15.7%), intravitreal rani-
bizumab and bevacizumab (14.3%), all 3 agents
(5.7%), intravitreal bevacizumab alone (4.3%), or in-
travitreal aﬂibercept alone (1%) but not at the same
time. Agents were switched during the course of the
study. There were 84 patients (88 eyes) reviewed at 4
years, and the mean visual acuity of these improved
from baseline to the 4-year visit in eyes with all neo-
vascular lesion subtypes except Type 3 NV where it
was stabilized (Type 1 NV [20/69–20/45]; Type 2 NV
[20/139–20/118]; Type 3 NV [20/78–20/79]; and
mixed lesions [20/171–20/133]). In the multivariate
analysis, a greater number of injections was consis-
tently found to be an independent predictor of better
vision at all the time points evaluated (6 months, 1, 2,
3, and 4 years). The mean number of injections per
year was 8.8, 7.7, 8.1, and 7.8, respectively. These
ﬁndings highlight the beneﬁt of TER across all lesion
types but show that the best visual outcomes occur in
eyes with Type 1 lesions.
Biomarkers. Biomarkers could be a useful adjunct
in determining TER strategy in patients who may be
nonresponders.45,46 In one study, a wide range of
1496 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2015  VOLUME 35  NUMBER 8
proteins was measured using reverse phase microar-
rays in the preinjection vitreous aspirates from nAMD
patients at monthly injection visits before TER.
PDGFRb Y751 and VEGFR2 Y951 were signiﬁcantly
increased in the vitreous of patients who responded
with worsening visual acuity (i.e., decrease $10
letters) during TER.45 However, the practical imple-
mentation of such assays and techniques in clinical
practice may limit the usefulness of their outcomes,
except in difﬁcult cases, such as recalcitrant patients
or those with a long disease history.
TER Algorithm
Based on the available scientiﬁc evidence described,
and the experience of the consensus panel, an algorithm
on the working deﬁnition of TER with anti-VEGF
agents in retinal diseases (nAMD, ME/RVO, DME)
was devised and is shown in Figure 1. The consensus
panel agreed that monthly injections should continue
until the following (maximum response) is observed:
1) complete resolution of SRF and intraretinal ﬂuid
(IRF) without new retinal hemorrhage or 2) no further
reduction of SRF or IRF on OCT for at least 2 consec-
utive visits in the absence of new retinal hemorrhage.
Some panel members would also include 3) no further
ﬂattening of serous or vascularized pigment epithelial
detachments and 4) no further improvement in visual
acuity, in their deﬁnition of maximal response. In gen-
eral, the consensus panel agreed that angiography is not
needed in most patients to determine when maximal
response has been reached. Once maximal response is
achieved, treatment intervals can be extended if there is
either a continued absence (preferred) or stabilization of
ﬂuid (i.e., no change in IRF or SRF for at least two
consecutive injections) on OCT and no new hemor-
rhage. As small ﬂuctuations in visual acuity are com-
monly observed in patients seen frequently for
intravitreal anti-VEGF injections, the consensus panel
felt that visual changes should be evaluated in the con-
text of the clinical examination and OCT ﬁndings if
they are to be used in guiding the treatment interval.
For example, visual acuity loss without signs of choroi-
dal neovascularization activity should not prompt the
need for aggressive treatment change, particularly as
visual acuity changes could be linked to other factors.
In some eyes with persistent IRF or SRF, a careful
review of the OCT and/or additional imaging with
angiography may help identify its source. For example,
in nAMD, disruption of the outer retinal architecture over
ﬁbrovascular tissue or the presence of Type 3 NV (retinal
angiomatous proliferation) may be associated with
persistent IRF despite monthly treatment. Fluorescein
angiography may be useful for detecting lesion growth
that may go unnoticed when imaging eyes frequently
with OCT. Indocyanine green angiography may help
identify polypoidal choroidal vasculopathy that can
show resistance to anti-VEGF therapy. In nAMD,
ME/RVO, and DME, OCT may show epiretinal
membranes or vitreomacular traction that may be
related to persistent IRF.
The consensus panel agreed that treatment can be
extended by up to 2 weeks at a time if the disease
remains stable. The “standard” maximum extension
period was considered to be 12 weeks; however, this
may also depend on the nature of the disease being
treated, for example, shorter for nAMD compared with
DME or ME/RVO, monocular patients, eyes at high
risk for hemorrhage (e.g., patients taking anticoagulants
or those with very large lesions), and the drug being
used.
If a patient shows signs of deterioration resulting
from disease activity, then the injection interval should
be shortened by 1 week to 2 weeks for a minor change
(e.g., small recurrences of ﬂuid or small increases in
previously stable ﬂuid on OCT, particularly when
these changes are accompanied by small degrees of
visual loss [,6 letters], or new small, extrafoveal sub-
retinal hemorrhage [even when not accompanied by
any vision loss]). If the deterioration is severe (e.g.,
large recurrences of ﬂuid or large increases in previ-
ously stable ﬂuid on OCT, particularly when these
changes are accompanied by large degrees of visual
loss [$6 letters], any subfoveal hemorrhage or large
extrafoveal macular hemorrhage [even when not
accompanied by any vision loss]), then the patient
should be reevaluated, and examination of the reasons
for deterioration (e.g., FA and/or indocyanine green
angiography) may need to be undertaken. In this situ-
ation of severe deterioration, reinduction with monthly
injection may be considered. Reassessment of treat-
ment interval can be considered once maximal
response after a reduced interval is again achieved
for two to three consecutive visits. Other longer-term
factors to consider following reinjection at maximum
interval (and depending on success) include dose
change, use of combination therapy, laser, medication
change, or treatment suspension.
Further considerations. Although there was some
concern regarding the potential development of geo-
graphic atrophy, the consensus panel agreed that, in
most instances, current evidence favors proactivity
with a TER approach rather than risking the negative
effects associated with undertreatment. At present,
there are insufﬁcient data to determine the association
between geographic atrophy and overtreatment
with anti-VEGF agents. Studies such as CATT
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Table 3. Criteria for Treatment Extension and Interval Shortening in TER Studies
Reference Criteria for Extension Fluid Recurrence (Interval Shortening)
Quantitative Assessments Used
OCT Other
Engelbert et al14 An absence of IRF and SRF on OCT 6 ﬂuid recurrences occurred in 10 patients during
the ﬁrst 24 months (after establishment of a deﬁned
interval)
TD-OCT Fundoscopy
(hemorrhage/tears)
Resolution of all hemorrhage During the cumulative observation period of 336
months, a total of 21 ﬂuid recurrences occurred
SD-OCT (ﬂuid/CRT)
Resolution of PED not required
Engelbert et al15 An absence of IRF and SRF at
foveola
Most eyes (15 of 18 [83%]) continued to manifest
extrafoveolar SRF throughout the course of
treatment
TD-OCT FA/ICGA
Resolution of all hemorrhage SD-OCT (new
hemorrhage/ﬂuid)
Fundoscopy
Resolution of PEDs and/or
extrafoveolar SRF that was
judged not to affect VA was not
required
Autoﬂuorescence
photography (NV/
hemorrhage/GA)
Gupta et al16 An absence of IRF or SRF on OCT 7 eyes (7.6%) demonstrated persistent signs of
exudation at each visit during FU
TD-OCT Slit-lamp biomicroscopy
Fourier-domain OCT
(hemorrhage/ﬂuid)
FA (hemorrhage)
Shienbaum et al17 An absence of IRF or SRF on OCT 5 eyes (6.8%) demonstrated persistent signs of
exudation at each FU visit
TD-OCT FA
Fourier-domain OCT
Fung et al18 An absence of IRF or SRF on OCT 71% (n = 5/7) had SRF and 57% (n = 4/7) had IRF
at 12 months in the 2.0 mg IVR group
SD-OCT (ﬂuid) Fundus examinations
50% (n = 1/2) had SRF and 50% (n = 1/2) had IRF
at 12 months in the 0.5 mg IVR group
FA
Toalster et al19 No signs of exudative disease: Persistent ﬂuid following last injection observed
48 times
SD-OCT (ﬂuid/
hemorrhage)
Fundus examinations
Vision loss $1 line associated with
ﬂuid detected by OCT
FA
Increase in CRT $100 mm
New-onset hemorrhage
New classic choroidal neovascular
membrane
Persistent ﬂuid following last
injection
Abedi et al20 No signs of CNV activity: Not reported TD-OCT (ﬂuid) Fundus examinations
No drop in VA of .5 letters from
the previous monthly visit
No persistent or new hemorrhage
on dilated fundus examination
An absence of IRF or SRF on OCT
1498
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Table 3. (Continued )
Reference Criteria for Extension Fluid Recurrence (Interval Shortening)
Quantitative Assessments Used
OCT Other
Rush et al21 An absence of IRF or SRF on OCT 72 patients (31.3%) could be extended beyond 12
weeks during the 12-month study; however, 51 of
those 72 patients developed recurrent exudation
beyond the 12-week follow-up interval and required
retreatment before the conclusion of the study
SD-OCT (ﬂuid) Fundus examinations
No macular hemorrhage on fundus
examination and without growth
or leakage of the CNV complex on
FA
FA/ICGA (NV/
hemorrhage/leakage)
Berg et al23
(LUCAS)
No signs of active neovascular
disease
No ﬂuid on OCT in 47% (IVB) and 65% (IVR) at Year
1 (P , 0.001)
TD-OCT Fundus examinations
SD-OCT FA (hemorrhage/
leakage/change in
lesion size)
Fourier-domain OCT
(ﬂuid)
Rayess et al24 No signs of CNV activity Average longest duration of successful extension was
11.4 weeks (Year 1), 13.7 weeks (Year 2), and 13.9
weeks (Year 3)
SD-OCT Slit-lamp biomicroscopy
(hemorrhage)Fourier-domain OCT
(ﬂuid/hemorrhage)
CNV, choroidal neovascularization; CRT, central retinal thickness; FA, ﬂuorescein angiography; FU, follow-up; GA, geographic atrophy; ICGA, indocyanine green angiography; IRF,
intraretinal ﬂuid; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; NV, neovascularization; OCT, optical coherence tomography; PED, pigment epithelial detachment; SD-OCT,
spectral-domain optical coherence tomography; SRF, subretinal ﬂuid; TD-OCT, time-domain optical coherence tomography; VA, visual acuity.
Table 4. An Overview of TER Studies With Anti-VEGF Agents in ME Secondary to RVO
Reference Design Treatment Efﬁcacy Results Safety Results Level
Brady et al28 • Retrospective TER approach with IVB or
IVR
• Mean VA: improved from 20/200 + 1 (BL) to
20/80
Not available 4
• FU: 6 months • Mean CMT: improved from 652 mm (BL) to
422 mm• Treatment-naive
CRVO
• 25 patients
Campochiaro et al29 • Prospective IVR • Edema resolution (no intraretinal ﬂuid for $6
months after last injection) in 50% (n = 17/34)
(BRVO) and 44% (n = 14/32) (CRVO)
Two patients had
events probably
related to vitreous
traction
3
• FU: 49 months Monthly visits (Year 1) • Patients with resolved CRVO had greater
improvement in BCVA (25.2 vs. 4.3 letters;
P = 0.002) than unresolved CRVO
• CRVO or BRVO 3-monthly visits (Year 2)
(extend-and-treat regimen)• 66 patients
Rush et al30 • Retrospective TER approach with IVB • Mean logMAR VA: improved from 0.54 to 0.24
(P , 0.001)
No systemic adverse
events
4
• FU: 12 months • Mean CMT: improved from 490.0 mm (BL) to
246.0 mm (P , 0.001)
• BRVO–ME • Mean injections (n): 8.2
• 52 patients
BCVA, best-correct visual acuity; BL, baseline; BRVO, branch retinal vein occlusion; CMT, central macular thickness; CRVO, central retinal vein occlusion; FU, follow-up; IVB,
intravitreal bevacizumab; IVR, intravitreal ranibizumab; logMAR, logarithm of the minimum angle of resolution; ME, macular edema; TER, treat-and-extend; RVO, retinal vein occlusion;
VA, visual acuity.
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Table 5. Key Ongoing Studies Including Those Using TER (Status: October 2014)
Title Disease
Main
Sponsor(s) Primary Drugs Study Identiﬁer(s) Objective(s) Primary Endpoint
Primary
Endpoints
Reported
A Phase IIIb,
multicenter,
randomized
study of the
safety,
tolerability and
efﬁcacy of IVR
0.5 mg given
monthly
compared to
TER
AMD Genentech Ranibizumab NCT01748292 To maintain an
exudation-free macula
with the fewest
number of ofﬁce visits,
tests, and injections
Mean change in ETDRS
visual acuity from Day
0 up to 24 months
January 01, 2015
T-REX
A Phase IIIb, 12-
month,
randomized,
visual acuity,
assessor-
masked,
multicenter
study of the
efﬁcacy and
safety of IVR 0.5
mg given
monthly
compared to
TER
AMD Novartis Ranibizumab NCT01948830 To evaluate the efﬁcacy
and safety of IVR
TER versus monthly
regimens
To demonstrate that the
TER is noninferior to
the monthly regimen
as assessed by the
change in BCVA from
baseline to Month 12
October 01,
2015TREND
A 12-month,
Phase IV,
randomized,
open-label,
multicenter
study to
compare the
efﬁcacy of IVR
0.5 mg PRN
versus IVT-AFL
2 mg bimonthly
AMD Novartis Ranibizumab NCT01958918 To compare IVR PRN
(BCVA loss and/or
SD-OCT disease
activity–guided
retreatment) versus
IVT-AFL bimonthly
To compare IVR 0.5 mg
PRN versus IVT-AFL
2 mg bimonthly on
SD-OCT CRT stability
(as measured by
mean CRT
ﬂuctuations between
Months 3 and 6)
July 01, 2016
Aﬂibercept SALT
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Table 5. (Continued )
Title Disease
Main
Sponsor(s) Primary Drugs Study Identiﬁer(s) Objective(s) Primary Endpoint
Primary
Endpoints
Reported
Phase IV study AMD Novartis Ranibizumab NCT02103738 To compare 2 IVR
treatment regimens
(standard of care and
TER); to achieve and
maintain a maximum
visual function beneﬁt;
to evaluate AMD
disease (based on
recurrence of disease
instability)—for
making treatment
decisions
Mean change in BCVA
from baseline to
Month 12
May 01, 2017
CAN-TREAT
OCT-guided TER
therapy using
IVT-AFL
AMD Regeneron Aﬂibercept NCT01773954 To evaluate the visual
outcomes and number
of injections required
during OCT-guided
TER with IVT-AFL
Mean change in BCVA
(ETDRS) letter score
November 30,
2014ATLAS
Treat-and-extend
therapy using
IVT-AFL for
previously
treated patients
exiting the wet
AMD extension
study (0910)
AMD ISS Aﬂibercept NCT01961414 To evaluate a TER
(increasing the time
between visits when
the disease is stable
and not getting worse)
of IVT-AFL 2.0 mg
Portion of patients who
maintain vision (loss
of #5 letters ETDRS
BCVA) from baseline
to 12 months
March 31, 2015
RANGE
A Phase I/II, open-
label,
multicenter,
randomized
study of the
safety,
tolerability, and
efﬁcacy of IVR
0.3 mg given
monthly
compared to
TER protocol
DME ISS Ranibizumab NCT01934556 To compare the visual
outcomes between
patients who are
treated with IVR as
monthly or TER
Mean change in vision
(ETDRS) at 24 months
November 01,
2016Laser
photocoagulation
TREX DME
(continued on next page)
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(Comparison of Age-related macular degeneration
Treatments Trials) and IVAN (a randomised con-
trolled trial of alternative treatments to Inhibit VEGF
in Age-related choroidal Neovascularisation) used
suboptimal imaging,4,5 making any distinction
between treatment effects and natural disease course
on geographic atrophy rates difﬁcult. Further study is
needed to determine if certain eyes at very high risk of
geographic atrophy (such as those with a very thin
choroid, reticular pseudodrusen, and possibly those
presenting with Type 3 NV [retinal angiomatous pro-
liferation])47–51 might be more safely managed with
a PRN regimen to reduce the risk of geographic atro-
phy progression. A new study in 91 patients (94 eyes)
showed that treatment-naive age-related macular
degeneration patients with Type 1 NV were signiﬁ-
cantly (P , 0.001) less likely to develop geographic
atrophy after anti-VEGF treatment compared with
other subtypes. The majority of patients received rani-
bizumab (63.8%), bevacizumab (9.6%), ranibizumab
plus bevacizumab (5.3%), ranibizumab plus intravi-
treal aﬂibercept (18.1%), or all 3 agents (3.2%); the
mean follow-up was 28.5 months and the mean num-
ber of injections was 17.4.48
The consensus panel also suggested that a TER
approach may reduce the risk of intraocular pressure
(IOP) elevation compared with monthly (but not PRN)
dosing; prevalence of sustained IOP was signiﬁcantly
higher when the intervals between injections were ,8
weeks compared with $8 weeks (17.6% vs. 6%, P =
0.009).52 In a 6-month retrospective study of 328 pa-
tients (449 eyes) with nAMD treated with intravitreal
ranibizumab or bevacizumab, 32 eyes (7.1%) developed
sustained IOP (deﬁned as absolute IOP .25 mmHg,
increase above baseline .10 mmHg, or IOP of .21
mmHg and increase of .5 mmHg) that was signiﬁ-
cantly linked to the number of injections (hazard ratio,
1.085; 95% conﬁdence interval, 1.06–1.11).53 Physi-
cians may also need to consider the differences between
transient postinjection IOP spikes related to injection
volume and needle gauge and sustained IOP elevation
occurring over the course of long-term treatment, and
risk factors such as preexisting glaucoma, ocular hyper-
tension, and rapid injection technique.54–56 Another
study in 22 patients (44 eyes) with nAMD showed no
signiﬁcant difference in retinal nerve ﬁber layer thick-
ness between eyes treated with intravitreal ranibizumab
using TER and the untreated fellow eye. Furthermore,
there was no difference in retinal nerve ﬁber layer thick-
ness in eyes treated with fewer or more than ﬁve
injections.57
At present, there are few studies to determine patient-
centered preferences for TER, including improvements
in compliance with less frequent visits and any
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tolerance to ﬂuid during optimization of dosing regi-
men, to make any strong conclusions regarding patient
choice. Surveys of Medicare beneﬁciaries (284,380
claims [2006–2008] and 459,237 claims [2014 update])
show that the frequency of anti-VEGF injections re-
mains lower than that recommended in clinical studies,
with high discontinuation rates (71% within 24
months).58,59 One 4-year longitudinal study that inves-
tigated the pattern of discontinuation in 555 patients
(600 eyes) with age-related macular degeneration trea-
ted with a variable intravitreal ranibizumab dosing reg-
imen from 2007 to 2011 found that 68% (408 eyes)
discontinued: 28% because of lack of response, 11%
failure to follow-up, 9% death, and 20% disease
inactivity. Treatment was resumed for 18% in this last
group, suggesting that eyes with inactivity should still
be monitored.60
It is possible that using a longer interval for
treatment follow-up could address some of the issues
observed in observational settings. In the long-term
study, Mrejen et al44 reported that the retention rate
was 64% over a mean follow-up of 3.6 years in 231
nAMD patients treated with anti-VEGF agents using
a TER approach. These ﬁndings indicate that a TER
may improve retention rates in the long term, but this
has yet to be investigated in large-scale observational
cohorts. About the issue of tolerance to ﬂuid, some
eyes with Type 1 NV managed with TER can have
Fig. 1. Algorithm showing the
working deﬁnition of TER. PED,
pigment epithelial detachment.
Table 6. Advantages and Disadvantages of TER Over PRN
Advantages Disadvantages
Fewer recurrences Overtreatment/may inject eye with a dry retina and achieve no VA change
Better long-term vision outcomes Does not identify the patient who may remain stable without treatment
(particularly for DME and RVO)
More likely to keep retina dry Potentially greater risk of geographical atrophy
Less patient visits Increased chance of getting an adverse event
More proactive Limited evidence
Guarantee of some injections No stop criteria in DME and RVO
Reduced risk of hemorrhage
Adherence, logistics, costs
Better disease control/stability
Individualized to patient
More predictable injection workload
DME, diabetic macular edema; PRN, pro re nata; RVO, retinal vein occlusion; TER, treat-and-extend; VA, visual acuity.
REVIEW ON TREAT-AND-EXTEND REGIMENS  FREUND ET AL 1503
good long-term visual outcomes with anti-VEGF ther-
apy despite some persistent SRF throughout the course
of treatment.15,61
From a cost perspective, the TER approach could be
associated with cost beneﬁts compared with monthly
regimens. As an early indication, Gupta et al16 re-
ported that the mean direct costs (per patient) of the
intravitreal ranibizumab TER used in their study
were US $16,114.52 (Year 1) and US $13,971.44
(Years 1–2), respectively; this was lower than that
observed over a 1-year period in MARINA/ANCHOR
(US $28,314.16). However, these cost estimates are
now outdated, and any cost analyses would beneﬁt
from inclusion of a wider cohort.
It must also be noted that a physician may consider
a number of reasons for not choosing TER, including
patient choice, preference for minimal number of
injections, particularly in bilateral eye disease, severe
glaucomawhere repeat pressure spikes may be a concern,
previous endophthalmitis, or other adverse reactions.
Conclusion
The aim of this consensus article is to consider the
best-practice approach to the use of a TER regimen
with anti-VEGF agents (intravitreal ranibizumab,
bevacizumab, and aﬂibercept) based on available
scientiﬁc evidence and clinical experience. There are
a number of limitations associated with this non-
systematic review and consensus. First, the published
studies of anti-VEGF TER are low-grade, nonregistra-
tion studies, which are not Level 1 type evidence. The
studies would therefore be subject to issues inherent
with the retrospective design of many of them. Other
issues include selection bias (including the exclusion
of noncompliant patients); the use of different imaging
techniques, with no correlation between OCT modal-
ities used; and Type II errors, arising from the lack of
monthly regimens for comparison of efﬁcacy and safety
outcomes. The consensus also represents the view of
clinical experts in the ﬁeld and is subject to bias and
limitations associated with health care systems in
different countries. The international, observational
AURA (a retrospective non-interventional study to
assess the effectiveness of existing Anti-vascular endo-
thelial growth factor treatment Regimens in patients
with wet Age-related macular degeneration) study
found that patients are undertreated with ranibizumab
in real-life settings; this may be because of the difﬁculty
of using monthly regimens in clinical practices.62 The
TER algorithm represents a useful guide that may lead
to an improvement in the minimum number of injec-
tions being used and may help address some of these
issues. The TER is practical and realistic in that it does
not overemphasize the need to achieve complete
absence of ﬂuid. It must be noted, however, that this
is a general guide and may not be applicable to unusual
cases in which physician expertise is required.
In summary, TER is considered a suitable approach
in a variety of retinal diseases—given that all eyes
differ in their need for injections (Table 6). A generic
TER approach could be used in most diseases, based
on achievement of a maximum (preferably optimal)
response followed by 1-week to 2-week extension
intervals that are guided by anatomical measures, with
visual changes as a secondary guide for interval exten-
sion. The maximum extension period may depend on
the anti-VEGF agent used. If disease activity
increases, the injection period should be shortened
by 2 weeks, with complete reassessment for a major
change (such as hemorrhage). There are also a number
of well-designed, randomized studies that are ongoing
that will help further reﬁne the optimal approach to
TER when these data become available.
Key words: treat-and-extend, anti-VEGF agents,
ranibizumab, bevacizumab, aﬂibercept, age-related
macular degeneration, diabetic macular edema, retinal
vein occlusion, algorithm.
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